Genotypes and haplotypes predisposing to myocardial infarction: A multilocus case-control study

European Heart Journal

Volumn 25, Issue 6, 2004, Pages 459-467

  Tobin, Martin D ^a   Braund, Peter S ^b   Burton, Paul R ^a   Thompson, John R ^a   Steeds, Richard ^c   Channer, Kevin ^c   Cheng, Suzanne ^d   Lindpaintner, Klaus ^e   Samani, Nilesh J ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d ROCHE MOLECULAR SYSTEMS   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Genetics; Myocardial infarction; Risk factors

Indexed keywords

ADDUCIN; ALPHA ADDUCIN; APOLIPOPROTEIN C3; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; CYSTEINE; GENOMIC DNA; GLUTAMINE; METHIONINE; PARAOXONASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEART INFARCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TECHNIQUE;

CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY STENOSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 1942488977     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2003.11.014     Document Type: Article

References (51)

1. Marenberg ME, Risch N, Berkman LF et al. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6.
2. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The regression growth evaluation statin study group. N Engl J Med 1998;338:86-93.
3. Yamada Y, Izawa H, Ichihara S et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002;347:1916-23.
4. Keavney B, McKenzie C, Parish S et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International studies of infarct survival (ISIS) collaborators. Lancet 2000;355:434-42.
5. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001;2:91-9.
6. Phillips MS, Lawrence R, Sachidanandam R et al. Chromosome-wide distribution of haplotype blocks and the role of recombination hot spots. Nat Genet 2003;33:382-7.
7. Gabriel SB, Schaffner SF, Nguyen H et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
8. Mander AP. Haplotype analysis in population-based association studies. Stata J 2001;1:58-75.
9. Schneider S, Roessli D, Excoffier L. Arlequin: A software for population genetics data analysis. In: 2.000 ed. Geneva, Switzerland: Genetics and Biometry Laboratory, University of Geneva; 2000.
10. Clayton D. SNPHAP: A program for estimating frequencies of large haplotypes of SNPs. In. 1.0 ed. Cambridge: Department of Medical Genetics, Cambridge Institute for Medical Research; 2002.
11. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
12. Schaid DJ, Rowland CM, Tines DE et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
13. Cheng S, Grow MA, Pallaud C et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999;9:936-49.
14. Steeds R, Adams M, Smith P et al. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects. Thromb Haemost 1998;79:980-4.
15. WHO. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979;59:607-9 [Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature].
16. Samani NJ, Martin DS, Brack M et al. Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty. Atherosclerosis 1996;125:209-16.
17. Hoppe C, Cheng S, Grow M et al. A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia. Br J Haematol 2001;114:718-20.
18. Abecasis GR, Cherny SS, Cookson WO et al. GRR: graphical representation of relationship errors. Bioinformatics 2001;17:742-3.
19. Davey Smith G, Ebrahim S. Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22.
20. Bitti PP, Murgia BS, Ticca A et al. Association between the ancestral haplotype HLA A30B18DR3 and multiple sclerosis in central Sardinia. Genet Epidemiol 2001;20:271-83.
21. Slatkin M, Excoffier L. Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity 1996;76(Pt 4):377-83.
22. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
23. Agresti A. Modelling patterns of agreement and disagreement. Stat Methods Med Res 1992;1:201-18.
24. McCullagh P, Nelder J. Generalized linear models. 2nd ed. London: Chapman and Hall; 1989.
25. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999;65:220-8.
26. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001;104:2641-4.
27. Joshi R, Gilligan DM, Otto E, et al. Primary structure and domain organization of human alpha and beta adducin. J Cell Biol 1991;115:665-75.
28. Matsuoka Y, Hughes CA, Bennett V. Adducin regulation. Definition of the calmodulin-binding domain and sites of phosphorylation by protein kinases A and C. J Biol Chem 1996;271:25157-66.
29. Manunta P, Cusi D, Barlassina C, et al. Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int 1998;53:1471-8.
30. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002;287:1680-9.
31. Hannuksela ML, Liinamaa MJ, Kesaniemi YA, et al. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 1994;110:35-44.
32. Dachet C, Poirier O, Cambien F, et al. New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 2000;20:507-15.
33. Klerkx AH, Tanck MW, Kastelein JJ, et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C->A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 2003;12:111-23.
34. Eiriksdottir G, Bolla MK, Thorsson B, et al. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis 2001;159:187-92.
35. Corbex M, Poirier O, Fumeron F, et al. Extensive association analysis between the CETP gene and coronary heart disease phenotypes reveals several putative functional polymorphisms and gene-environment interaction. Genet Epidemiol 2000;19:64-80.
36. Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the west of Scotland coronary prevention study. Eur Heart J 2003;24:1833-42.
37. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53.
38. Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6.
39. Mackness B, Mackness MI, Arrol S, et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57-60.
40. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997;17:2935-9.
41. Sanghera DK, Saha N, Aston CE, et al. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997;17:1067-73.
42. Ruiz J, Blanche H, James RW, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869-72.
43. Turban S, Fuentes F, Ferlic L, et al. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis 2001;154:633-40.
44. Gardemann A, Philipp M, Hess K, et al. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000;152:421-31.
45. Sanghera DK, Aston CE, Saha N, et al. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
46. Wang X, Fan Z, Huang J, et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 2003;23:328-34.
47. Breslow J. Familial disorders of high density lipoprotein metabolism. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic basis of inherited disease. New York: McGraw-Hill; 1995. p. 1251-66.
48. Peacock RE, Hamsten A, Johansson J, et al. Associations of genotypes at the apolipoprotein AI-CIII-AIV, apolipoprotein B and lipoprotein lipase gene loci with coronary atherosclerosis and high density lipoprotein subclasses. Clin Genet 1994;46:273-82.
49. Dammerman M, Sandkuijl LA, Halaas JL, et al. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993;90:4562-6.
50. Surguchov AP, Page GP, Smith L, et al. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996;16:941-7.
51. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002;32:650-4.